Screener
Bio-Techne TECH SG&A
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Bio-Techne’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056302
| Line item | Quarter Ended / March 31, 2026 | Quarter Ended / March 31, 2025 | Nine Months Ended / March 31, 2026 | Nine Months Ended / March 31, 2025 |
|---|---|---|---|---|
| Cost of sales | 103,127 | 101,625 | 306,170 | 311,211 |
| Gross margin | 208,288 | 214,556 | 587,677 | 591,460 |
| Operating expenses: | ||||
| Selling, general and administrative | 109,338 | 151,269 | 339,242 | 391,881 |
| Research and development | 23,455 | 24,579 | 70,821 | 73,464 |
| Total operating expenses | 132,793 | 175,848 | 410,063 | 465,345 |
| Operating income | 75,495 | 38,708 | 177,614 | 126,115 |
| Other income (expense) | (4,270) | (434) | (7,614) | (4,793) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Bio-Techne's SG&A?
- Bio-Techne (TECH) reported SG&A of $109.34M in Q1 2026.
- How has Bio-Techne's SG&A changed year-over-year?
- Bio-Techne's SG&A decreased by 27.7% year-over-year, from $151.27M to $109.34M.
- What is the long-term trend for Bio-Techne's SG&A?
- Over 3 years (2022 to 2025), Bio-Techne's SG&A has grown at a 16.4% compound annual growth rate (CAGR), from $372.77M to $588.52M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Bio-Techne's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude